- Home
- GWRS vs NYXH Comparison
GWRS vs NYXH Comparison
Compare GWRS & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRS
- NYXH
- Stock Information
- Founded
- GWRS 2003
- NYXH 2009
- Country
- GWRS United States
- NYXH Belgium
- Employees
- GWRS N/A
- NYXH N/A
- Industry
- GWRS Water Supply
- NYXH Medical/Dental Instruments
- Sector
- GWRS Utilities
- NYXH Health Care
- Exchange
- GWRS Nasdaq
- NYXH Nasdaq
- Market Cap
- GWRS 321.8M
- NYXH 261.1M
- IPO Year
- GWRS 2010
- NYXH 2021
- Fundamental
- Price
- GWRS $11.96
- NYXH $10.85
- Analyst Decision
- GWRS
- NYXH Strong Buy
- Analyst Count
- GWRS 0
- NYXH 5
- Target Price
- GWRS N/A
- NYXH $17.00
- AVG Volume (30 Days)
- GWRS 39.4K
- NYXH 64.9K
- Earning Date
- GWRS 03-05-2025
- NYXH 03-13-2025
- Dividend Yield
- GWRS 2.51%
- NYXH N/A
- EPS Growth
- GWRS N/A
- NYXH N/A
- EPS
- GWRS 0.27
- NYXH N/A
- Revenue
- GWRS $51,809,000.00
- NYXH $5,668,079.00
- Revenue This Year
- GWRS $0.79
- NYXH $22.93
- Revenue Next Year
- GWRS $4.58
- NYXH $411.04
- P/E Ratio
- GWRS $44.53
- NYXH N/A
- Revenue Growth
- GWRS 0.10
- NYXH 32.65
- 52 Week Low
- GWRS $11.05
- NYXH $4.27
- 52 Week High
- GWRS $13.98
- NYXH $20.00
- Technical
- Relative Strength Index (RSI)
- GWRS 52.56
- NYXH 77.88
- Support Level
- GWRS $11.05
- NYXH $8.86
- Resistance Level
- GWRS $11.94
- NYXH $10.08
- Average True Range (ATR)
- GWRS 0.25
- NYXH 0.60
- MACD
- GWRS 0.10
- NYXH 0.22
- Stochastic Oscillator
- GWRS 100.00
- NYXH 84.81
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operate within the State of Arizona.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.